KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Cash from Investing Activities: 2020-2025

Historic Cash from Investing Activities for AbCellera Biologics (ABCL) over the last 6 years, with Sep 2025 value amounting to $36.5 million.

  • AbCellera Biologics' Cash from Investing Activities rose 886.70% to $36.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.3 million, marking a year-over-year decrease of 21.29%. This contributed to the annual value of $121.4 million for FY2024, which is 154.91% up from last year.
  • As of Q3 2025, AbCellera Biologics' Cash from Investing Activities stood at $36.5 million, which was up 214.70% from -$31.8 million recorded in Q2 2025.
  • AbCellera Biologics' Cash from Investing Activities' 5-year high stood at $52.1 million during Q2 2024, with a 5-year trough of -$282.0 million in Q3 2022.
  • Over the past 3 years, AbCellera Biologics' median Cash from Investing Activities value was $3.7 million (recorded in 2024), while the average stood at -$7.9 million.
  • In the last 5 years, AbCellera Biologics' Cash from Investing Activities slumped by 6,840.18% in 2021 and then spiked by 886.70% in 2025.
  • Over the past 5 years, AbCellera Biologics' Cash from Investing Activities (Quarterly) stood at -$1.1 million in 2021, then plummeted by 1,385.03% to -$17.1 million in 2022, then slumped by 42.55% to -$24.3 million in 2023, then skyrocketed by 246.79% to $35.7 million in 2024, then surged by 886.70% to $36.5 million in 2025.
  • Its last three reported values are $36.5 million in Q3 2025, -$31.8 million for Q2 2025, and $7.9 million during Q1 2025.